Obesity: Current and potential pharmacotherapeutics and targets

Abdeen, 2015, Mechanism underlying the weight loss and complications of Roux-en-Y gastric bypass. Review, Obes Surg Abizaid, 2006, Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite, J Clin Invest, 116, 3229, 10.1172/JCI29867 ADIPEX-P® Prescribing Information Agmo, 1995, Reward and reinforcement produced by drinking sucrose: Two processes that may depend on different neurotransmitters, Pharmacol Biochem Behav, 52, 403, 10.1016/0091-3057(95)00128-J Ahituv, 2006, A PYY Q62P variant linked to human obesity, Hum Mol Genet, 15, 387, 10.1093/hmg/ddi455 al'Absi, 2011, Circulating leptin levels are associated with increased craving to smoke in abstinent smokers, Pharmacol Biochem Behav, 97, 509, 10.1016/j.pbb.2010.10.004 Alhadeff, 2012, GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake, Endocrinology, 153, 647, 10.1210/en.2011-1443 Allison, 2012, Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP), Obesity (Silver Spring), 20, 330, 10.1038/oby.2011.330 American Psychiatric Association, 2013, 350 Anderson, 2007, Orlistat for the management of overweight individuals and obesity: A review of potential for the 60-mg, over-the-counter dosage, Expert Opin Pharmacother, 8, 1733, 10.1517/14656566.8.11.1733 Angeles-Castellanos, 2007, Restricted feeding schedules phase shift daily rhythms of c-Fos and protein Per1 immunoreactivity in corticolimbic regions in rats, Neuroscience, 144, 344, 10.1016/j.neuroscience.2006.08.064 Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), Obesity (Silver Spring), 21, 935, 10.1002/oby.20309 Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun, 257, 79, 10.1006/bbrc.1999.0255 Arterburn, 2013, A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass, Obes Surg, 23, 93, 10.1007/s11695-012-0802-1 Asnicar, 2001, Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet, Endocrinology, 142, 4394, 10.1210/endo.142.10.8416 Astarita, 2006, Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus), Am J Physiol Regul Integr Comp Physiol, 290, R1407, 10.1152/ajpregu.00664.2005 Astrup, 2008, Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomized, double-blind, placebo-controlled trial, Lancet, 372, 1906, 10.1016/S0140-6736(08)61525-1 Astrup, 2008, Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease, Obesity (Silver Spring), 16, 1363, 10.1038/oby.2008.56 Avenell, 2004, Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement, Health Technol Assess, 8, 1 Axel, 2010, Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat, Neuropsychopharmacology, 35, 1464, 10.1038/npp.2010.16 Azari, 2014, Vagal afferents are not necessary for the satiety effect of the gut lipid messenger oleoylethanolamide, Am J Physiol Regul Integr Comp Physiol, 307, R167, 10.1152/ajpregu.00067.2014 Backhed, 2004, The gut microbiota as an environmental factor that regulates fat storage, Proc Natl Acad Sci U S A, 101, 15718, 10.1073/pnas.0407076101 Baggio, 2004, Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure, Gastroenterology, 127, 546, 10.1053/j.gastro.2004.04.063 Bailey, 2008, A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on “BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat,” by Bariohay et al, Am J Physiol Regul Integr Comp Physiol, 295, R1048, 10.1152/ajpregu.90701.2008 Bala, 2014, Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-epsilon pathway and modulated by endogenous H2S, Front Physiol, 5, 420, 10.3389/fphys.2014.00420 Ballinger, 1995, Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations, Clin Sci (Lond), 89, 375, 10.1042/cs0890375 Batterham, 2003, The gut hormone peptide YY regulates appetite, Ann N Y Acad Sci, 994, 162, 10.1111/j.1749-6632.2003.tb03176.x Bays, 2014, Canagliflozin: effects in overweight and obese subjects without diabetes mellitus, Obesity (Silver Spring), 22, 1042, 10.1002/oby.20663 Ben-Menachem, 2003, Predictors of weight loss in adults with topiramate-treated epilepsy, Obes Res, 11, 556, 10.1038/oby.2003.78 Benoit, 2002, The catabolic action of insulin in the brain is mediated by melanocortins, J Neurosci, 22, 9048, 10.1523/JNEUROSCI.22-20-09048.2002 Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992 Berridge, 2000, Measuring hedonic impact in animals and infants: microstructure of affective taste reactivity patterns, Neurosci Biobehav Rev, 24, 173, 10.1016/S0149-7634(99)00072-X Berridge, 1998, What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?, Brain Res Brain Res Rev, 28, 309, 10.1016/S0165-0173(98)00019-8 Berryman, 2013, The GH/IGF-1 axis in obesity: Pathophysiology and therapeutic considerations, Nat Rev Endocrinol, 9, 346, 10.1038/nrendo.2013.64 Berthoud, 2002, Multiple neural systems controlling food intake and body weight, Neurosci Biobehav Rev, 26, 393, 10.1016/S0149-7634(02)00014-3 Berthoud, 2011, Metabolic and hedonic drives in the neural control of appetite: Who is the boss?, Curr Opin Neurobiol, 21, 888, 10.1016/j.conb.2011.09.004 Bi, 2001, A role for NPY overexpression in the dorsomedial hypothalamus in hyperphagia and obesity of OLETF rats, Am J Physiol Regul Integr Comp Physiol, 281, R254, 10.1152/ajpregu.2001.281.1.R254 Bi, 2002, Actions of CCK in the controls of food intake and body weight: lessons from the CCK-A receptor deficient OLETF rat, Neuropeptides, 36, 171, 10.1054/npep.2002.0895 Billes, 2014, Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss, Pharmacol Res, 84, 1, 10.1016/j.phrs.2014.04.004 Bishop, 2009, Lifestyle risk factors for atherosclerosis in adults with type 1 diabetes, Diab Vasc Dis Res, 6, 269, 10.1177/1479164109346359 Blache, 1988, Oxyntomodulin and glicentin: Brain-gut peptides in the rat, Endocrinology, 123, 2782, 10.1210/endo-123-6-2782 Blevins, 2000, Brain regions where cholecystokinin suppresses feeding in rats, Brain Res, 860, 1, 10.1016/S0006-8993(99)02477-4 Bloomgarden, 2002, Obesity, hypertension, and insulin resistance, Diabetes Care, 25, 2088, 10.2337/diacare.25.11.2088 Blundell, 1977, Is there a role for serotonin (5-hydroxytryptamine) in feeding?, Int J Obes (Lond), 1, 15 Blundell, 1991, Pharmacological approaches to appetite suppression, Trends Pharmacol Sci, 12, 147, 10.1016/0165-6147(91)90532-W Bookout, 2006, Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network, Cell, 126, 789, 10.1016/j.cell.2006.06.049 Borgland, 2009, Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers, J Neurosci, 29, 11215, 10.1523/JNEUROSCI.6096-08.2009 Bragulat, 2010, Food-related odor probes of brain reward circuits during hunger: A pilot FMRI study, Obesity (Silver Spring), 18, 1566, 10.1038/oby.2010.57 Brange, 1993, Insulin structure and stability, Pharm Biotechnol, 5, 315, 10.1007/978-1-4899-1236-7_11 Bray, 2003, A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity, Obes Res, 11, 722, 10.1038/oby.2003.102 Bredella, 2009, Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity, J Clin Endocrinol Metab, 94, 3995, 10.1210/jc.2009-0438 Bremner, 1996, Noradrenergic mechanisms in stress and anxiety: II. Clinical studies, Synapse, 23, 39, 10.1002/(SICI)1098-2396(199605)23:1<39::AID-SYN5>3.0.CO;2-I Broberger, 1998, The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice, Proc Natl Acad Sci U S A, 95, 15043, 10.1073/pnas.95.25.15043 Brown, 1996, Pathophysiology and management of the serotonin syndrome, Ann Pharmacother, 30, 527, 10.1177/106002809603000517 Bruijnzeel, 2011, Effects of insulin and leptin in the ventral tegmental area and arcuate hypothalamic nucleus on food intake and brain reward function in female rats, Behav Brain Res, 219, 254, 10.1016/j.bbr.2011.01.020 Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor, Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 Callahan, 2004, Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans, J Clin Endocrinol Metab, 89, 1319, 10.1210/jc.2003-031267 Calu, 2014, The use of the reinstatement model to study relapse to palatable food seeking during dieting, Neuropharmacology, 76 Pt B, 395, 10.1016/j.neuropharm.2013.04.030 Camilleri, 2015, Peripheral mechanisms in appetite regulation, Gastroenterology, 148, 1219, 10.1053/j.gastro.2014.09.016 Campfield, 1996, The OB protein (leptin) pathway — A link between adipose tissue mass and central neural networks, Horm Metab Res, 28, 619, 10.1055/s-2007-979867 Carvelli, 2002, PI 3-kinase regulation of dopamine uptake, J Neurochem, 81, 859, 10.1046/j.1471-4159.2002.00892.x Cason, 2013, Role of orexin/hypocretin in conditioned sucrose-seeking in rats, Psychopharmacology (Berl), 226, 155, 10.1007/s00213-012-2902-y Cason, 2010, Role of orexin/hypocretin in reward-seeking and addiction: Implications for obesity, Physiol Behav, 100, 419, 10.1016/j.physbeh.2010.03.009 Cass, 1994, Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake, Neurosci Lett, 176, 259, 10.1016/0304-3940(94)90096-5 CDC Report Chaperon, 1998, Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats, Psychopharmacology (Berl), 135, 324, 10.1007/s002130050518 Charmot, 2012, Non-systemic drugs: A critical review, Curr Pharm Des, 18, 1434, 10.2174/138161212799504858 Chelikani, 2005, Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats, Am J Physiol Regul Integr Comp Physiol, 288, R1695, 10.1152/ajpregu.00870.2004 Chen, 2000, Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass, Nat Genet, 26, 97, 10.1038/79254 Chen, 2015, RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals, J Clin Endocrinol Metab, 100, 1639, 10.1210/jc.2014-4024 Chen, 1997, Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors, Mol Pharmacol, 52, 1164, 10.1124/mol.52.6.1164 Chen, 2002, Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity, Endocrinology, 143, 2469, 10.1210/endo.143.7.8903 Cho, 2009, Cigarette smoking is an independent risk factor for type 2 diabetes: A four-year community-based prospective study, Clin Endocrinol (Oxf), 71, 679, 10.1111/j.1365-2265.2009.03586.x Choi, 2002, TRH decreases food intake and increases water intake and body temperature in rats, Physiol Behav, 77, 1, 10.1016/S0031-9384(02)00784-9 Christensen, 2007, Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomized trials, Lancet, 370, 1706, 10.1016/S0140-6736(07)61721-8 Christopoulos, 1999, Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product, Mol Pharmacol, 56, 235, 10.1124/mol.56.1.235 Cincotta, 1996, Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects, Diabetes Care, 19, 667, 10.2337/diacare.19.6.667 Clasey, 2001, Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors, J Clin Endocrinol Metab, 86, 3845, 10.1210/jcem.86.8.7731 Cleary, 1996, Naloxone effects on sucrose-motivated behavior, Psychopharmacology (Berl), 126, 110, 10.1007/BF02246345 Clemmensen, 2015, Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice, EMBO Mol Med, 7, 288, 10.15252/emmm.201404508 Colantuoni, 2001, Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain, Neuroreport, 12, 3549, 10.1097/00001756-200111160-00035 Colditz, 1990, Weight as a risk factor for clinical diabetes in women, Am J Epidemiol, 132, 501, 10.1093/oxfordjournals.aje.a115686 Cole, 2015, Orexin/hypocretin-1 receptor antagonism selectively reduces cue-induced feeding in sated rats and recruits medial prefrontal cortex and thalamus, Sci Rep, 5, 16143, 10.1038/srep16143 Colman, 2012, The FDA's assessment of two drugs for chronic weight management, N Engl J Med, 367, 1577, 10.1056/NEJMp1211277 Colon-Gonzalez, 2013, Obesity pharmacotherapy: What is next?, Mol Aspects Med, 34, 71, 10.1016/j.mam.2012.10.005 Cota, 2007, Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function, Endocrinology, 148, 1574, 10.1210/en.2005-1649 Cottone, 2008, Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food, Neuropsychopharmacology, 33, 524, 10.1038/sj.npp.1301430 Courtney, 2007, Rapidly progressive renal failure associated with successful pharmacotherapy for obesity, Nephrol Dial Transplant, 22, 621, 10.1093/ndt/gfl684 Cowley, 1999, Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat, Neuron, 24, 155, 10.1016/S0896-6273(00)80829-6 Cowley, 2001, Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus, Nature, 411, 480, 10.1038/35078085 Cristino, 2013, Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons, Proc Natl Acad Sci U S A, 110, E2229, 10.1073/pnas.1219485110 Cryer, 2012, Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes, Endocrinology, 153, 1039, 10.1210/en.2011-1499 Cuchel, 2013, Microsomal transfer protein inhibition in humans, Curr Opin Lipidol, 24, 246, 10.1097/MOL.0b013e32836139df Cummings, 2006, Ghrelin and the short- and long-term regulation of appetite and body weight, Physiol Behav, 89, 71, 10.1016/j.physbeh.2006.05.022 Cummings, 2001, A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans, Diabetes, 50, 1714, 10.2337/diabetes.50.8.1714 Davidson, 1957, Calorigenic action of glucagon, Nature, 180, 1124, 10.1038/1801124a0 Davies, 1992, Effects on ingestive behavior in rats of the alpha 1-adrenoceptor agonist cirazoline, Eur J Pharmacol, 210, 11, 10.1016/0014-2999(92)90645-K Davis, 2011, Leptin regulates energy balance and motivation through action at distinct neural circuits, Biol Psychiatry, 69, 668, 10.1016/j.biopsych.2010.08.028 Davis, 2009, Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity, Neuroendocrinology, 89, 152, 10.1159/000170586 Davis, 2008, Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat, Behav Neurosci, 122, 1257, 10.1037/a0013111 de Lecea, 1998, The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity, Proc Natl Acad Sci U S A, 95, 322, 10.1073/pnas.95.1.322 De Olmos, 1999, The concepts of the ventral striatopallidal system and extended amygdala, 1 De Simone, 2008, Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs?, Curr Pharm Des, 14, 655, 10.2174/138161208783877820 Degen, 2001, The effect of cholecystokinin in controlling appetite and food intake in humans, Peptides, 22, 1265, 10.1016/S0196-9781(01)00450-8 Di Marzo, 2009, The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation, Int J Obes (Lond), 33, S18, 10.1038/ijo.2009.67 Dickson, 2010, Blockade of central nicotine acetylcholine receptor signaling attenuate ghrelin-induced food intake in rodents, Neuroscience, 171, 1180, 10.1016/j.neuroscience.2010.10.005 Dickson, 2012, The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors, J Neurosci, 32, 4812, 10.1523/JNEUROSCI.6326-11.2012 DiPatrizio, 2011, Endocannabinoid signal in the gut controls dietary fat intake, Proc Natl Acad Sci U S A, 108, 12904, 10.1073/pnas.1104675108 DiPatrizio, 2015, Fasting stimulates 2-AG biosynthesis in the small intestine: Role of cholinergic pathways, Am J Physiol Regul Integr Comp Physiol, 309, R805, 10.1152/ajpregu.00239.2015 DiPatrizio, 2013, Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats, FASEB J, 27, 2513, 10.1096/fj.13-227587 DiPatrizio, 2015, Intestinal lipid-derived signals that sense dietary fat, J Clin Invest, 125, 891, 10.1172/JCI76302 Druce, 2005, Ghrelin increases food intake in obese as well as lean subjects, Int J Obes (Lond), 29, 1130, 10.1038/sj.ijo.0803001 Drucker, 2006, Enhancing the action of incretin hormones: A new whey forward?, Endocrinology, 147, 3171, 10.1210/en.2006-0494 Drucker, 2007, The role of gut hormones in glucose homeostasis, J Clin Invest, 117, 24, 10.1172/JCI30076 Drucker, 1988, Glucagon gene expression in vertebrate brain, J Biol Chem, 263, 13475, 10.1016/S0021-9258(18)68261-4 Dufresne, 2006, Cholecystokinin and gastrin receptors, Physiol Rev, 86, 805, 10.1152/physrev.00014.2005 Dumont, 1995, Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands, J Pharmacol Exp Ther, 272, 673 Dushay, 2012, Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Care, 35, 4, 10.2337/dc11-0931 Dwoskin, 2006, Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent, CNS Drug Rev, 12, 178, 10.1111/j.1527-3458.2006.00178.x Ebihara, 1999, Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action, Diabetes, 48, 2028, 10.2337/diabetes.48.10.2028 Eckel, 2005, The metabolic syndrome, Lancet, 365, 1415, 10.1016/S0140-6736(05)66378-7 Eggink, 2014, TGR5 ligands as potential therapeutics in inflammatory diseases, Int J Interferon Cytokine Mediator Res, 6, 27 Eipper, 1980, Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides, Endocr Rev, 1, 1, 10.1210/edrv-1-1-1 Elias, 1998, Leptin activates hypothalamic CART neurons projecting to the spinal cord, Neuron, 21, 1375, 10.1016/S0896-6273(00)80656-X Elkind-Hirsch, 2008, Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome, J Clin Endocrinol Metab, 93, 2670, 10.1210/jc.2008-0115 Elmquist, 1998, Unraveling the central nervous system pathways underlying responses to leptin, Nat Neurosci, 1, 445, 10.1038/2164 European Medicines Agency Evans, 2004, PPARs and the complex journey to obesity, Nat Med, 10, 355, 10.1038/nm1025 Everitt, 1987, Studies of instrumental behavior with sexual reinforcement in male rats (Rattus norvegicus): I. Control by brief visual stimuli paired with a receptive female, J Comp Psychol, 101, 395, 10.1037/0735-7036.101.4.395 Everitt, 2005, Neural systems of reinforcement for drug addiction: from actions to habits to compulsion, Nat Neurosci, 8, 1481, 10.1038/nn1579 Fang, 2015, Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance, Nat Med, 21, 159, 10.1038/nm.3760 FDA FDA draft guidance FDA draft guidance FDA FDA drug safety communication FDA FDA FDA FDA Fei, 1997, Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues, Proc Natl Acad Sci U S A, 94, 7001, 10.1073/pnas.94.13.7001 Fekete, 2000, J Neurosci, 20, 1550, 10.1523/JNEUROSCI.20-04-01550.2000 Ferraz, 2004, Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion, Kidney Int, 66, 676, 10.1111/j.1523-1755.2004.00790.x Figlewicz, 2004, Intraventricular insulin and leptin reverse place preference conditioned with high-fat diet in rats, Behav Neurosci, 118, 479, 10.1037/0735-7044.118.3.479 Figlewicz, 2006, Intraventricular insulin and leptin decrease sucrose self-administration in rats, Physiol Behav, 89, 611, 10.1016/j.physbeh.2006.07.023 Figlewicz, 2003, Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat, Brain Res, 964, 107, 10.1016/S0006-8993(02)04087-8 Figlewicz, 2001, Leptin reverses sucrose-conditioned place preference in food-restricted rats, Physiol Behav, 73, 229, 10.1016/S0031-9384(01)00486-3 Figlewicz, 1994, Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra, Brain Res, 644, 331, 10.1016/0006-8993(94)91698-5 Fleming, 2013, New obesity agents: Lorcaserin and phentermine/topiramate, Ann Pharmacother, 47, 1007, 10.1345/aph.1R779 Flint, 2001, The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity, Int J Obes Relat Metab Disord, 25, 781, 10.1038/sj.ijo.0801627 Foote, 1983, Nucleus locus ceruleus: New evidence of anatomical and physiological specificity, Physiol Rev, 63, 844, 10.1152/physrev.1983.63.3.844 Forman, 1995, Identification of a nuclear receptor that is activated by farnesol metabolites, Cell, 81, 687, 10.1016/0092-8674(95)90530-8 Frassetto, 2008, Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5-HT6 receptor, Brain Res, 1236, 140, 10.1016/j.brainres.2008.08.012 Freund, 2003, Role of endogenous cannabinoids in synaptic signaling, Physiol Rev, 83, 1017, 10.1152/physrev.00004.2003 Fride, 2002, Endocannabinoids in the central nervous system — An overview, Prostaglandins Leukot Essent Fatty Acids, 66, 221, 10.1054/plef.2001.0360 Friedman, 2011, Electrical stimulation of the lateral habenula produces an inhibitory effect on sucrose self-administration, Neuropharmacology, 60, 381, 10.1016/j.neuropharm.2010.10.006 Fruebis, 2001, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc Natl Acad Sci U S A, 98, 2005, 10.1073/pnas.98.4.2005 Fu, 2007, Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine, J Biol Chem, 282, 1518, 10.1074/jbc.M607809200 Fu, 2003, Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha, Nature, 425, 90, 10.1038/nature01921 Fu, 2005, Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats, Neuropharmacology, 48, 1147, 10.1016/j.neuropharm.2005.02.013 Fujimori, 2008, Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models, J Pharmacol Exp Ther, 327, 268, 10.1124/jpet.108.140210 Fuke, 2001, The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression, Pharmacogenomics J, 1, 152, 10.1038/sj.tpj.6500026 Fulton, 2006, Leptin regulation of the mesoaccumbens dopamine pathway, Neuron, 51, 811, 10.1016/j.neuron.2006.09.006 Gadde, 2009, Combination pharmaceutical therapies for obesity, Expert Opin Pharmacother, 10, 921, 10.1517/14656560902824152 Gadde, 2011, Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomized, placebo-controlled, phase 3 trial, Lancet, 377, 1341, 10.1016/S0140-6736(11)60205-5 Gadde, 2003, Zonisamide for weight loss in obese adults: A randomized controlled trial, JAMA, 289, 1820, 10.1001/jama.289.14.1820 Gaetani, 2010, The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin, J Neurosci, 30, 8096, 10.1523/JNEUROSCI.0036-10.2010 Gaetani, 2003, Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide, Neuropsychopharmacology, 28, 1311, 10.1038/sj.npp.1300166 Gannon, 2006, PRX-07034, a potent and selective 5-HT6 receptor antagonist, reduces food intake and body weight in rats, J Pharmacol Sci, 101, 124 Garcia, 2005, Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution, Mol Pharmacol, 68, 102, 10.1124/mol.104.009092 Garfield, 2009, Pharmacological targeting of the serotonergic system for the treatment of obesity, J Physiol, 587, 49, 10.1113/jphysiol.2008.164152 Garvey, 2012, Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study, Am J Clin Nutr, 95, 297, 10.3945/ajcn.111.024927 Gearhardt, 2009, Preliminary validation of the Yale Food Addiction Scale, Appetite, 52, 430, 10.1016/j.appet.2008.12.003 Gearhardt, 2013, Preliminary validation of the Yale Food Addiction Scale for children, Eat Behav, 14, 508, 10.1016/j.eatbeh.2013.07.002 Gearhardt, 2012, An examination of the food addiction construct in obese patients with binge eating disorder, Int J Eat Disord, 45, 657, 10.1002/eat.20957 Geiger, 2008, Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats, FASEB J, 22, 2740, 10.1096/fj.08-110759 George, 2014, New and emerging drug molecules against obesity, J Cardiovasc Pharmacol Ther, 19, 65, 10.1177/1074248413501017 Georgescu, 2005, The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance, J Neurosci, 25, 2933, 10.1523/JNEUROSCI.1714-04.2005 Ghitza, 2006, The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: A role of CRF1 receptors, Neuropsychopharmacology, 31, 2188, 10.1038/sj.npp.1300964 Giuliano, 2012, Inhibition of opioid transmission at the mu-opioid receptor prevents both food seeking and binge-like eating, Neuropsychopharmacology, 37, 2643, 10.1038/npp.2012.128 Goldman, 1985, Postsynaptic alpha 2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine, Eur J Pharmacol, 115, 11, 10.1016/0014-2999(85)90578-3 Gomez, 2002, A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding, J Neurosci, 22, 9612, 10.1523/JNEUROSCI.22-21-09612.2002 Gong, 2006, Cannabinoid CB2 receptors: immunohistochemical localization in rat brain, Brain Res, 1071, 10, 10.1016/j.brainres.2005.11.035 Gordon, 2000, Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly, Biochim Biophys Acta, 1486, 72, 10.1016/S1388-1981(00)00049-4 Grandt, 1994, Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36, Regul Pept, 51, 151, 10.1016/0167-0115(94)90204-6 Grandt, 1994, Characterization of two forms of peptide YY, PYY(1–36) and PYY(3–36), in the rabbit, Peptides, 15, 815, 10.1016/0196-9781(94)90035-3 Greenberg, 1996, The controls of fat intake, Psychosom Med, 58, 559, 10.1097/00006842-199611000-00004 Greenway, 2009, Rational design of a combination medication for the treatment of obesity, Obesity (Silver Spring), 17, 30, 10.1038/oby.2008.461 Grill, 2012, Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance, Cell Metab, 16, 296, 10.1016/j.cmet.2012.06.015 Gros, 1993, Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line, Endocrinology, 133, 631, 10.1210/endo.133.2.8102095 Gruetzmann, 2000, Bay 13–9952 (implitapide), an inhibitor of microsomal triglyceride transfer protein (MTP), blocks secretion of Apo-B lipoproteins, Atherosclerosis, 151, 91, 10.1016/S0021-9150(00)80416-5 Grundy, 2005, A constellation of complications: The metabolic syndrome, Clin Cornerstone, 7, 36, 10.1016/S1098-3597(05)80066-3 Gu, 2013, Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication, J Comp Neurol, 521, 2235, 10.1002/cne.23282 Gustafson, 2013, Lorcaserin (Belviq): A selective serotonin 5-HT2C agonist in the treatment of obesity, P T, 38, 525 Gutzwiller, 2004, Glucagon-like peptide 1 (GLP-1) and eating, Physiol Behav, 82, 17, 10.1016/j.physbeh.2004.04.019 Haass-Koffler, 2015, Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving, Transl Psychiatry, 5, e646, 10.1038/tp.2015.140 Hahn, 1998, Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons, Nat Neurosci, 1, 271, 10.1038/1082 Halaas, 1995, Weight-reducing effects of the plasma protein encoded by the obese gene, Science, 269, 543, 10.1126/science.7624777 Hampp, 2013, Use of prescription antiobesity drugs in the United States, Pharmacotherapy, 33, 1299, 10.1002/phar.1342 Hara, 2001, Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity, Neuron, 30, 345, 10.1016/S0896-6273(01)00293-8 Harrold, 2008, Autoradiographic analysis of ghrelin receptors in the rat hypothalamus, Brain Res, 1196, 59, 10.1016/j.brainres.2007.12.055 Harrold, 2012, CNS regulation of appetite, Neuropharmacology, 63, 3, 10.1016/j.neuropharm.2012.01.007 Harrold, 2002, Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: A role for endogenous cannabinoids in driving appetite for palatable food?, Brain Res, 952, 232, 10.1016/S0006-8993(02)03245-6 Hatoum, 2012, Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery, J Clin Endocrinol Metab, 97, E1023, 10.1210/jc.2011-3432 Hauptman, 2000, Orlistat in the long-term treatment of obesity in primary care settings, Arch Fam Med, 9, 160, 10.1001/archfami.9.2.160 Haynes, 2002, Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice, Regul Pept, 104, 153, 10.1016/S0167-0115(01)00358-5 Heal, 2009, Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders, Br J Clin Pharmacol, 68, 861, 10.1111/j.1365-2125.2009.03549.x Heal, 2012, What is the prognosis for new centrally-acting anti-obesity drugs?, Neuropharmacology, 63, 132, 10.1016/j.neuropharm.2012.01.017 Heinz, 2000, Genotype influences in vivo dopamine transporter availability in human striatum, Neuropsychopharmacology, 22, 133, 10.1016/S0893-133X(99)00099-8 Hendricks, 2014, Addiction potential of phentermine prescribed during long-term treatment of obesity, Int J Obes (Lond), 38, 292, 10.1038/ijo.2013.74 Hervieu, 2000, The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat, Eur J Neurosci, 12, 1194, 10.1046/j.1460-9568.2000.00008.x Hervieu, 2001, Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord, Neuroscience, 103, 777, 10.1016/S0306-4522(01)00033-1 Heymsfield, 1999, Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial, JAMA, 282, 1568, 10.1001/jama.282.16.1568 Heymsfield, 2000, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults, Arch Intern Med, 160, 1321, 10.1001/archinte.160.9.1321 Hillebrand, 2002, Neuropeptides, food intake and body weight regulation: A hypothalamic focus, Peptides, 23, 2283, 10.1016/S0196-9781(02)00269-3 Hodge, 2016, Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?, Diabetes Obes Metab, 18, 439, 10.1111/dom.12636 Hogan, 1987, Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase, Int J Obes (Lond), 11, 35 Hollander, 2003, Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial, Diabetes Care, 26, 784, 10.2337/diacare.26.3.784 Hommel, 2006, Leptin receptor signaling in midbrain dopamine neurons regulates feeding, Neuron, 51, 801, 10.1016/j.neuron.2006.08.023 Hotta, 2000, Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients, Arterioscler Thromb Vasc Biol, 20, 1595, 10.1161/01.ATV.20.6.1595 Howell, 2015, Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder, Pharmacol Rev, 67, 176, 10.1124/pr.114.009514 Hughes, 2013, Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women, Obesity (Silver Spring), 21, 1782, 10.1002/oby.20356 Hussain, 2008, New approaches to target microsomal triglyceride transfer protein, Curr Opin Lipidol, 19, 572, 10.1097/MOL.0b013e328312707c Huszar, 1997, Targeted disruption of the melanocortin-4 receptor results in obesity in mice, Cell, 88, 131, 10.1016/S0092-8674(00)81865-6 Hyde, 1983, Effects of area postrema/caudal medial nucleus of solitary tract lesions on food intake and body weight, Am J Physiol, 244, R577 Ibrahim, 2003, Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels, Endocrinology, 144, 1331, 10.1210/en.2002-221033 Igarashi, 2015, Feeding-induced oleoylethanolamide mobilization is disrupted in the gut of diet-induced obese rodents, Biochim Biophys Acta, 1851, 1218, 10.1016/j.bbalip.2015.05.006 Ignar, 2011, Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist, J Pharmacol Exp Ther, 339, 24, 10.1124/jpet.111.180943 Ioannides-Demos, 2011, Pharmacotherapies for obesity: Past, current, and future therapies, J Obes, 2011, 179674, 10.1155/2011/179674 Izzo, 2009, Peripheral endocannabinoid dysregulation in obesity: Relation to intestinal motility and energy processing induced by food deprivation and re-feeding, Br J Pharmacol, 158, 451, 10.1111/j.1476-5381.2009.00183.x Jaber, 1997, The dopamine transporter: A crucial component regulating dopamine transmission, Mov Disord, 12, 629, 10.1002/mds.870120502 Jackson, 2014, Investigational drugs in Phase II clinical trials for the treatment of obesity: Implications for future development of novel therapies, Expert Opin Investig Drugs, 23, 1055, 10.1517/13543784.2014.918952 Jamshidi, 2001, Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats, Br J Pharmacol, 134, 1151, 10.1038/sj.bjp.0704379 Jerlhag, 2007, Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens, Addict Biol, 12, 6, 10.1111/j.1369-1600.2006.00041.x Jerlhag, 2009, Requirement of central ghrelin signaling for alcohol reward, Proc Natl Acad Sci U S A, 106, 11318, 10.1073/pnas.0812809106 Jessen, 2005, Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion, Am J Physiol Endocrinol Metab, 288, E194, 10.1152/ajpendo.00149.2004 Jiang, 2015, Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction, Nat Commun, 6, 10166, 10.1038/ncomms10166 Johannsson, 2007, Management of adult growth hormone deficiency, Endocrinol Metab Clin North Am, 36, 203, 10.1016/j.ecl.2006.11.012 Johnson, 2010, Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats, Nat Neurosci, 13, 635, 10.1038/nn.2519 Jorgensen, 1994, Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: A double-blind placebo-controlled study, Metabolism, 43, 872, 10.1016/0026-0495(94)90269-0 Judge, 2008, Prolonged hyperphagia with high-fat feeding contributes to exacerbated weight gain in rats with adult-onset obesity, Am J Physiol Regul Integr Comp Physiol, 295, R773, 10.1152/ajpregu.00727.2007 Jung, 2012, 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism, Cell Metab, 15, 299, 10.1016/j.cmet.2012.01.021 Kadowaki, 2005, Adiponectin and adiponectin receptors, Endocr Rev, 26, 439, 10.1210/er.2005-0005 Kalra, 1999, Interacting appetite-regulating pathways in the hypothalamic regulation of body weight, Endocr Rev, 20, 68 Kanai, 1994, The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose, J Clin Invest, 93, 397, 10.1172/JCI116972 Kang, 2010, Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity, Diabetes Obes Metab, 12, 876, 10.1111/j.1463-1326.2010.01242.x Kanoski, 2011, Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4, Endocrinology, 152, 3103, 10.1210/en.2011-0174 Kapur, 2013, First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus, BMC Pharmacol Toxicol, 14, 26, 10.1186/2050-6511-14-26 Karamadoukis, 2009, An unusual complication of treatment with orlistat, Clin Nephrol, 71, 430, 10.5414/CNP71430 Kawamata, 2003, A G protein-coupled receptor responsive to bile acids, J Biol Chem, 278, 9435, 10.1074/jbc.M209706200 Kay, 2014, Hindbrain orexin 1 receptors influence palatable food intake, operant responding for food, and food-conditioned place preference in rats, Psychopharmacology (Berl), 231, 419, 10.1007/s00213-013-3248-9 Keesey, 1997, Body weight set-points: determination and adjustment, J Nutr, 127, 1875S, 10.1093/jn/127.9.1875S Kelley, 2004, Ventral striatal control of appetitive motivation: Role in ingestive behavior and reward-related learning, Neurosci Biobehav Rev, 27, 765, 10.1016/j.neubiorev.2003.11.015 Kelley, 2002, The neuroscience of natural rewards: Relevance to addictive drugs, J Neurosci, 22, 3306, 10.1523/JNEUROSCI.22-09-03306.2002 Kelly, 2015, The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours, Psychopharmacology (Berl), 232, 305, 10.1007/s00213-014-3666-3 Kelly, 1990, Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance, Neuroendocrinology, 52, 268, 10.1159/000125597 Kenny, 2011, Common cellular and molecular mechanisms in obesity and drug addiction, Nat Rev Neurosci, 12, 638, 10.1038/nrn3105 Kernie, 2000, BDNF regulates eating behavior and locomotor activity in mice, EMBO J, 19, 1290, 10.1093/emboj/19.6.1290 Kieffer, 1999, The glucagon-like peptides, Endocr Rev, 20, 876, 10.1210/edrv.20.6.0385 Kievit, 2013, Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques, Diabetes, 62, 490, 10.2337/db12-0598 Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, Diabetes Care, 30, 1487, 10.2337/dc06-2375 Kim, 2015, Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial, Diabetes Obes Metab, 17, 566, 10.1111/dom.12457 Kim, 2011, A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: Biochemical, pharmacodynamic, pharmacokinetic, and safety profile, J Pharmacol Exp Ther, 337, 775, 10.1124/jpet.110.177527 Kim, 2007, Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732, J Mol Endocrinol, 38, 455, 10.1677/jme.1.02165 Kirkham, 2002, Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol, Br J Pharmacol, 136, 550, 10.1038/sj.bjp.0704767 Kok, 2006, Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women, J Clin Endocrinol Metab, 91, 3236, 10.1210/jc.2005-2529 Kolterman, 2003, Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes, J Clin Endocrinol Metab, 88, 3082, 10.1210/jc.2002-021545 Koob, 2010, Neurocircuitry of addiction, Neuropsychopharmacology, 35, 217, 10.1038/npp.2009.110 Kopelman, 2010, Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: Comparison with orlistat (Xenical), Obesity (Silver Spring), 18, 108, 10.1038/oby.2009.155 Korbonits, 2004, Ghrelin: update on a novel hormonal system, Eur J Endocrinol, 151, S67, 10.1530/eje.0.151S067 Koyama, 2014, Obesity attenuates D2 autoreceptor-mediated inhibition of putative ventral tegmental area dopaminergic neurons, Physiol Rep, 2, e12004, 10.14814/phy2.12004 Krude, 1998, Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans, Nat Genet, 19, 155, 10.1038/509 Kurth, 2002, Body mass index and the risk of stroke in men, Arch Intern Med, 162, 2557, 10.1001/archinte.162.22.2557 Lam, 2008, Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors, Endocrinology, 149, 1323, 10.1210/en.2007-1321 Launay, 2002, Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension, Nat Med, 8, 1129, 10.1038/nm764 Lavin, 1998, Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate, Am J Clin Nutr, 68, 591, 10.1093/ajcn/68.3.591 le Roux, 2006, Attenuated peptide YY release in obese subjects is associated with reduced satiety, Endocrinology, 147, 3, 10.1210/en.2005-0972 Lee, 1996, Abnormal splicing of the leptin receptor in diabetic mice, Nature, 379, 632, 10.1038/379632a0 Lee, 2003, The effects of adjunctive topiramate on cognitive function in patients with epilepsy, Epilepsia, 44, 339, 10.1046/j.1528-1157.2003.27402.x Lefebvre, 2006, Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis, J Clin Invest, 116, 571, 10.1172/JCI27989 Leggio, 2013, Fasting-induced increase in plasma ghrelin is blunted by intravenous alcohol administration: A within-subject placebo-controlled study, Psychoneuroendocrinology, 38, 3085, 10.1016/j.psyneuen.2013.09.005 Leggio, 2014, Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: A preliminary investigation, Biol Psychiatry, 76, 734, 10.1016/j.biopsych.2014.03.019 Leibowitz, 1982, Distribution of alpha-adrenergic, beta-adrenergic and dopaminergic receptors in discrete hypothalamic areas of rat, Brain Res, 233, 97, 10.1016/0006-8993(82)90933-7 Leibowitz, 1984, Chronic norepinephrine injection into the hypothalamic paraventricular nucleus produces hyperphagia and increased body weight in the rat, Pharmacol Biochem Behav, 21, 801, 10.1016/S0091-3057(84)80022-2 Leibowitz, 1988, Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action, Clin Neuropharmacol, 11, S51 Leinninger, 2009, Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding, Cell Metab, 10, 89, 10.1016/j.cmet.2009.06.011 Lent, 2013, Smoking and alcohol use in gastric bypass patients, Eat Behav, 14, 460, 10.1016/j.eatbeh.2013.08.008 Levin, 2002, Reduced central leptin sensitivity in rats with diet-induced obesity, Am J Physiol Regul Integr Comp Physiol, 283, R941, 10.1152/ajpregu.00245.2002 Li, 2013, Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity, Nat Commun, 4, 2384, 10.1038/ncomms3384 Liddle, 1985, Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction, J Clin Invest, 75, 1144, 10.1172/JCI111809 List, 2009, Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes, Diabetologia, 52, 1647, 10.1007/s00125-009-1402-z Lonneman, 2013, Phentermine/Topiramate extended-release capsules (qsymia) for weight loss, P T, 38, 446 Lu, 1994, Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor, Nature, 371, 799, 10.1038/371799a0 Lutter, 2009, Homeostatic and hedonic signals interact in the regulation of food intake, J Nutr, 139, 629, 10.3945/jn.108.097618 Lutz, 1994, Reduction of food intake in rats by intraperitoneal injection of low doses of amylin, Physiol Behav, 55, 891, 10.1016/0031-9384(94)90076-0 MacDonald, 2007, A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans, PLoS Biol, 5, e143, 10.1371/journal.pbio.0050143 Macht, 2007, Immediate effects of chocolate on experimentally induced mood states, Appetite, 49, 667, 10.1016/j.appet.2007.05.004 Maffei, 1995, Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus, Proc Natl Acad Sci U S A, 92, 6957, 10.1073/pnas.92.15.6957 Mahler, 2007, Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances ‘liking’ of a sweet reward, Neuropsychopharmacology, 32, 2267, 10.1038/sj.npp.1301376 Mains, 1980, Biosynthetic studies on ACTH, beta-endorphin, and alpha-melanotropin in the rat, Ann N Y Acad Sci, 343, 94, 10.1111/j.1749-6632.1980.tb47245.x Makishima, 1999, Identification of a nuclear receptor for bile acids, Science, 284, 1362, 10.1126/science.284.5418.1362 Maldonado, 2006, Involvement of the endocannabinoid system in drug addiction, Trends Neurosci, 29, 225, 10.1016/j.tins.2006.01.008 Malik, 2008, Ghrelin modulates brain activity in areas that control appetitive behavior, Cell Metab, 7, 400, 10.1016/j.cmet.2008.03.007 Mansour, 1994, Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study, J Comp Neurol, 350, 412, 10.1002/cne.903500307 Marcus, 2001, Differential expression of orexin receptors 1 and 2 in the rat brain, J Comp Neurol, 435, 6, 10.1002/cne.1190 Maresz, 2007, Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells, Nat Med, 13, 492, 10.1038/nm1561 Margulis, 2012, Use of topiramate in pregnancy and risk of oral clefts, Am J Obstet Gynecol, 207, e401 Mark, 1994, An appetitively conditioned taste elicits a preferential increase in mesolimbic dopamine release, Pharmacol Biochem Behav, 48, 651, 10.1016/0091-3057(94)90327-1 Marks, 1991, Gut hormones in glucose homeostasis, Proc Nutr Soc, 50, 545, 10.1079/PNS19910067 Marks-Kaufman, 1980, Morphine selectively influences macronutrient intake in the rat, Pharmacol Biochem Behav, 12, 427, 10.1016/0091-3057(80)90048-9 Marks-Kaufman, 1981, Modifications of nutrient selection induced by naloxone in rats, Psychopharmacology (Berl), 74, 321, 10.1007/BF00432739 Marsh, 2002, Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism, Proc Natl Acad Sci U S A, 99, 3240, 10.1073/pnas.052706899 Martel, 1996, Mesolimbic dopaminergic system activity as a function of food reward: A microdialysis study, Pharmacol Biochem Behav, 53, 221, 10.1016/0091-3057(95)00187-5 Martin, 2011, Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure, J Clin Endocrinol Metab, 96, 837, 10.1210/jc.2010-1848 Martin, 1977, Decreased feeding in rats following hepatic-portal infusion of glucagon, Physiol Behav, 19, 461, 10.1016/0031-9384(77)90218-9 Maruyama, 2002, Identification of membrane-type receptor for bile acids (M-BAR), Biochem Biophys Res Commun, 298, 714, 10.1016/S0006-291X(02)02550-0 Matheny, 2011, Region-specific diet-induced and leptin-induced cellular leptin resistance includes the ventral tegmental area in rats, Neuropharmacology, 60, 480, 10.1016/j.neuropharm.2010.11.002 Matson, 1999, Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight, Am J Physiol, 276, R1038 Matsuzawa, 2010, Establishment of a concept of visceral fat syndrome and discovery of adiponectin, Proc Jpn Acad Ser B Phys Biol Sci, 86, 131, 10.2183/pjab.86.131 Mayo, 2003, International Union of Pharmacology. XXXV. The glucagon receptor family, Pharmacol Rev, 55, 167, 10.1124/pr.55.1.6 McElroy, 2007, Topiramate for the treatment of binge eating disorder associated with obesity: A placebo-controlled study, Biol Psychiatry, 61, 1039, 10.1016/j.biopsych.2006.08.008 McNeely, 1998, Orlistat, Drugs, 56, 241, 10.2165/00003495-199856020-00007 Mebel, 2012, Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake, Eur J Neurosci, 36, 2336, 10.1111/j.1460-9568.2012.08168.x Melis, 2004, Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors, J Neurosci, 24, 53, 10.1523/JNEUROSCI.4503-03.2004 Melis, 2007, The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food, Neurosci Lett, 419, 231, 10.1016/j.neulet.2007.04.012 Menendez, 1991, Insulin and the paraventricular hypothalamus: modulation of energy balance, Brain Res, 555, 193, 10.1016/0006-8993(91)90342-S Merchenthaler, 1999, Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system, J Comp Neurol, 403, 261, 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5 Meye, 2013, Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity, Mol Psychiatry, 18, 1294, 10.1038/mp.2012.145 Midtvedt, 1974, Microbial bile acid transformation, Am J Clin Nutr, 27, 1341, 10.1093/ajcn/27.11.1341 Miller, 1993, Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation, Genes Dev, 7, 454, 10.1101/gad.7.3.454 Mindell, 1990, Corn oil and mineral oil stimulate sham feeding in rats, Physiol Behav, 48, 283, 10.1016/0031-9384(90)90314-T Mokdad, 2001, The continuing epidemics of obesity and diabetes in the United States, JAMA, 286, 1195, 10.1001/jama.286.10.1195 Moller, 2009, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects, Endocr Rev, 30, 152, 10.1210/er.2008-0027 Mondal, 2005, Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus, Regul Pept, 126, 55, 10.1016/j.regpep.2004.08.038 Montani, 2002, Pathways from obesity to hypertension: from the perspective of a vicious triangle, Int J Obes Relat Metab Disord, 26, S28, 10.1038/sj.ijo.0802125 Montgomery, 2013, Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression, Horm Metab Res, 45, 471, 10.1055/s-0032-1331767 Moran, 1992, Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK, Am J Physiol, 262, R46 Moreau, 2011, Corn oil, 273 Morrison, 2007, Neurobiology of nutrition and obesity, Nutr Rev, 65, 517, 10.1111/j.1753-4887.2007.tb00277.x Munro, 1968, Comparison of continuous and intermittent anorectic therapy in obesity, Br Med J, 1, 352, 10.1136/bmj.1.5588.352 Myers, 2008, Mechanisms of leptin action and leptin resistance, Annu Rev Physiol, 70, 537, 10.1146/annurev.physiol.70.113006.100707 Nair, 1987, Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency, J Clin Endocrinol Metab, 64, 896, 10.1210/jcem-64-5-896 Nam, 2001, Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients, Int J Obes Relat Metab Disord, 25, 1101, 10.1038/sj.ijo.0801636 Narayanaswami, 2013, Diet-induced obesity: dopamine transporter function, impulsivity and motivation, Int J Obes (Lond), 37, 1095, 10.1038/ijo.2012.178 Naslund, 1999, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans, Am J Physiol, 277, R910 Nathan, 2012, Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel mu-opioid receptor inverse agonist, J Clin Pharmacol, 52, 464, 10.1177/0091270011399577 Nathan, 2011, Neuropsychiatric adverse effects of centrally acting antiobesity drugs, CNS Neurosci Ther, 17, 490, 10.1111/j.1755-5949.2010.00172.x National Health and Examination Survey Navarrete, 2013, Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine, Neuropsychopharmacology, 38, 2515, 10.1038/npp.2013.157 NCI Nielsen, 2008, Growth hormone signaling in vivo in human muscle and adipose tissue: Impact of insulin, substrate background, and growth hormone receptor blockade, J Clin Endocrinol Metab, 93, 2842, 10.1210/jc.2007-2414 Ng, 2014, Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013, Lancet, 384, 766, 10.1016/S0140-6736(14)60460-8 Nogueiras, 2012, The opioid system and food intake: Homeostatic and hedonic mechanisms, Obes Facts, 5, 196, 10.1159/000338163 Obici, 2002, Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats, Nat Neurosci, 5, 566, 10.1038/nn0602-861 O'Dell, 2007, Nicotine deprivation effect’ in rats with intermittent 23-hour access to intravenous nicotine self-administration, Pharmacol Biochem Behav, 86, 346, 10.1016/j.pbb.2007.01.004 O'Dell, 2014, Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes, Addict Biol, 19, 1006, 10.1111/adb.12074 Oltmans, 1983, Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob), Brain Res, 273, 369, 10.1016/0006-8993(83)90865-X Onaga, 2002, Multiple regulation of peptide YY secretion in the digestive tract, Peptides, 23, 279, 10.1016/S0196-9781(01)00609-X Onaivi, 2006, Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain, Ann N Y Acad Sci, 1074, 514, 10.1196/annals.1369.052 O'Neil, 2012, Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study, Obesity (Silver Spring), 20, 1426, 10.1038/oby.2012.66 Opland, 2010, Modulation of the mesolimbic dopamine system by leptin, Brain Res, 1350, 65, 10.1016/j.brainres.2010.04.028 Osei-Hyiaman, 2005, Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide, Neuroendocrinology, 81, 273, 10.1159/000087925 Osei-Hyiaman, 2005, Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, J Clin Invest, 115, 1298, 10.1172/JCI200523057 Osei-Hyiaman, 2008, Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice, J Clin Invest, 118, 3160, 10.1172/JCI34827 Oveisi, 2004, Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration, Pharmacol Res, 49, 461, 10.1016/j.phrs.2003.12.006 Padwal, 2007, Drug treatments for obesity: Orlistat, sibutramine, and rimonabant, Lancet, 369, 71, 10.1016/S0140-6736(07)60033-6 Palkovits, 1999, Interconnections between the neuroendocrine hypothalamus and the central autonomic system. Geoffrey Harris Memorial Lecture, Kitakyushu, Japan, October 1998, Front Neuroendocrinol, 20, 270, 10.1006/frne.1999.0186 Palmiter, 2007, Is dopamine a physiologically relevant mediator of feeding behavior?, Trends Neurosci, 30, 375, 10.1016/j.tins.2007.06.004 Parker, 2012, Hypothalamic neuropeptides and the regulation of appetite. [Review], Neuropharmacology, 63, 18, 10.1016/j.neuropharm.2012.02.004 Papaleo, 2007, Decreased motivation to eat in mu-opioid receptor-deficient mice, Eur J Neurosci, 25, 3398, 10.1111/j.1460-9568.2007.05595.x Parseus, 2016, Microbiota-induced obesity requires farnesoid X receptor, Gut, 10.1136/gutjnl-2015-310283 Pecina, 2005, Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness?, J Neurosci, 25, 11777, 10.1523/JNEUROSCI.2329-05.2005 Pecina, 2003, Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards, J Neurosci, 23, 9395, 10.1523/JNEUROSCI.23-28-09395.2003 Pelchat, 2004, Images of desire: Food-craving activation during fMRI, Neuroimage, 23, 1486, 10.1016/j.neuroimage.2004.08.023 Penick, 1961, Depression of food intake induced in healthy subjects by glucagon, N Engl J Med, 264, 893, 10.1056/NEJM196105042641801 Penney, 2015, The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: A systematic review, Int J Obes (Lond), 39, 1565, 10.1038/ijo.2015.115 Peruzzo, 2000, A second look at the barriers of the medial basal hypothalamus, Exp Brain Res, 132, 10, 10.1007/s002219900289 Peterson, 1999, Psychosocial and pharmacological treatment of eating disorders: a review of research findings, J Clin Psychol, 55, 685, 10.1002/(SICI)1097-4679(199906)55:6<685::AID-JCLP3>3.0.CO;2-Y Petry, 2008, Overweight and obesity are associated with psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions, Psychosom Med, 70, 288, 10.1097/PSY.0b013e3181651651 Peyron, 1998, Neurons containing hypocretin (orexin) project to multiple neuronal systems, J Neurosci, 18, 9996, 10.1523/JNEUROSCI.18-23-09996.1998 Piccoli, 2012, Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats, Neuropsychopharmacology, 37, 1999, 10.1038/npp.2012.48 Pijl, 2000, Bromocriptine: A novel approach to the treatment of type 2 diabetes, Diabetes Care, 23, 1154, 10.2337/diacare.23.8.1154 Piomelli, 2005, The endocannabinoid system: A drug discovery perspective, Curr Opin Investig Drugs, 6, 672 Piomelli, 2013, A fatty gut feeling, Trends Endocrinol Metab, 24, 332, 10.1016/j.tem.2013.03.001 Pischon, 2005, Association between dietary factors and plasma adiponectin concentrations in men, Am J Clin Nutr, 81, 780, 10.1093/ajcn/81.4.780 Pissios, 2009, Animals models of MCH function and what they can tell us about its role in energy balance, Peptides, 30, 2040, 10.1016/j.peptides.2009.05.002 Pissios, 2006, Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions, Endocr Rev, 27, 606, 10.1210/er.2006-0021 Pi-Sunyer, 2015, Liraglutide in weight management, N Engl J Med, 373, 1781 Pocai, 2014, Action and therapeutic potential of oxyntomodulin, Mol Metab, 3, 241, 10.1016/j.molmet.2013.12.001 Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 Polonsky, 2008, Gastric banding to treat obesity: Band-aid or breakthrough?, Nat Clin Pract Endocrinol Metab, 4, 421, 10.1038/ncpendmet0889 Polston, 2013, Roux-en-Y gastric bypass increases intravenous ethanol self-administration in dietary obese rats, PLoS One, 8, e83741, 10.1371/journal.pone.0083741 Poole, 2010, Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system, Neurogastroenterol Motil, 22, e227 Porte, 2002, Leptin and insulin action in the central nervous system, Nutr Rev, 60, S20, 10.1301/002966402320634797 Prawitt, 2011, Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity, Diabetes, 60, 1861, 10.2337/db11-0030 Provensi, 2014, Satiety factor oleoylethanolamide recruits the brain histaminergic system to inhibit food intake, Proc Natl Acad Sci U S A, 111, 11527, 10.1073/pnas.1322016111 Qi, 2004, Adiponectin acts in the brain to decrease body weight, Nat Med, 10, 524, 10.1038/nm1029 Qu, 1996, A role for melanin-concentrating hormone in the central regulation of feeding behaviour, Nature, 380, 243, 10.1038/380243a0 Quarta, 2010, CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance, Cell Metab, 11, 273, 10.1016/j.cmet.2010.02.015 Ravinet Trillou, 2004, CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity, Int J Obes Relat Metab Disord, 28, 640, 10.1038/sj.ijo.0802583 Ravussin, 2009, Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy, Obesity (Silver Spring), 17, 1736, 10.1038/oby.2009.184 Read, 1992, Role of gastrointestinal factors in hunger and satiety in man, Proc Nutr Soc, 51, 7, 10.1079/PNS19920004 Rehfeld, 2001, The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33, J Clin Endocrinol Metab, 86, 251 Richard, 2000, Influence of topiramate in the regulation of energy balance, Nutrition, 16, 961, 10.1016/S0899-9007(00)00452-4 Richard, 2015, Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system, PLoS One, 10, e0119034, 10.1371/journal.pone.0119034 Richards, 2008, Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats, Psychopharmacology (Berl), 199, 109, 10.1007/s00213-008-1136-5 Richardson, 2014, Insulin resistant rats display enhanced rewarding effects of nicotine, Drug Alcohol Depend, 140, 205, 10.1016/j.drugalcdep.2014.03.028 Richardson, 1996, Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy, J Neurosci Methods, 66, 1, 10.1016/0165-0270(95)00153-0 Riegel, 2004, Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area, J Neurosci, 24, 11070, 10.1523/JNEUROSCI.3695-04.2004 Rodgers, 2012, Anti-obesity drugs: past, present and future, Dis Model Mech, 5, 621, 10.1242/dmm.009621 Rodriguez de Fonseca, 2001, An anorexic lipid mediator regulated by feeding, Nature, 414, 209, 10.1038/35102582 Roevens, 1999, Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP), Atherosclerosis, 144, 38, 10.1016/S0021-9150(99)80144-0 Rolls, 2011, Taste, olfactory and food texture reward processing in the brain and obesity, Int J Obes (Lond), 35, 550, 10.1038/ijo.2010.155 Rosenstock, 2010, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes, Diabetes Care, 33, 1173, 10.2337/dc09-1203 Rossi, 1998, A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo, Endocrinology, 139, 4428, 10.1210/endo.139.10.6332 Roth, 2008, Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies, Proc Natl Acad Sci U S A, 105, 7257, 10.1073/pnas.0706473105 Rushing, 2001, Inhibition of central amylin signaling increases food intake and body adiposity in rats, Endocrinology, 142, 5035, 10.1210/endo.142.11.8593 Sadry, 2013, Emerging combinatorial hormone therapies for the treatment of obesity and T2DM, Nat Rev Endocrinol, 9, 425, 10.1038/nrendo.2013.47 Sainsbury, 2002, Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice, Proc Natl Acad Sci U S A, 99, 8938, 10.1073/pnas.132043299 Sakurai, 1998, Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior, Cell, 92, 573, 10.1016/S0092-8674(00)80949-6 Sam, 2012, The role of the gut/brain axis in modulating food intake, Neuropharmacology, 63, 46, 10.1016/j.neuropharm.2011.10.008 Sanchis-Segura, 2004, Reduced sensitivity to reward in CB1 knockout mice, Psychopharmacology (Berl), 176, 223, 10.1007/s00213-004-1877-8 Sanger, 2010, The hungry stomach: physiology, disease, and drug development opportunities, Front Pharmacol, 1, 145 Saper, 2002, The need to feed: Homeostatic and hedonic control of eating, Neuron, 36, 199, 10.1016/S0896-6273(02)00969-8 Sarica, 2008, Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor, Obesity (Silver Spring), 16, 1579, 10.1038/oby.2008.244 Sarkar, 2003, Endocrinology, 144, 281, 10.1210/en.2002-220675 Sayin, 2013, Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist, Cell Metab, 17, 225, 10.1016/j.cmet.2013.01.003 Scarpace, 2005, Leptin resistance exacerbates diet-induced obesity and is associated with diminished maximal leptin signalling capacity in rats, Diabetologia, 48, 1075, 10.1007/s00125-005-1763-x Scarpace, 2009, Leptin resistance: A prediposing factor for diet-induced obesity, Am J Physiol Regul Integr Comp Physiol, 296, R493, 10.1152/ajpregu.90669.2008 Scheen, 2011, Sibutramine on cardiovascular outcome, Diabetes Care, 34, S114, 10.2337/dc11-s205 Schur, 2009, Activation in brain energy regulation and reward centers by food cues varies with choice of visual stimulus, Int J Obes (Lond), 33, 653, 10.1038/ijo.2009.56 Schwartz, 2008, The lipid messenger OEA links dietary fat intake to satiety, Cell Metab, 8, 281, 10.1016/j.cmet.2008.08.005 Schwartz, 2000, Central nervous system control of food intake, Nature, 404, 661, 10.1038/35007534 Sclafani, 1998, Pharmacology of food conditioned preferences, Appetite, 31, 406, 10.1006/appe.1998.0211 Scott, 2007, The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size, Am J Physiol Regul Integr Comp Physiol, 293, R983, 10.1152/ajpregu.00323.2007 Sears, 2010, Regulation of nucleus accumbens activity by the hypothalamic neuropeptide melanin-concentrating hormone, J Neurosci, 30, 8263, 10.1523/JNEUROSCI.5858-09.2010 Self, 1998, Relapse to drug-seeking: Neural and molecular mechanisms, Drug Alcohol Depend, 51, 49, 10.1016/S0376-8716(98)00065-9 Selvakumar, 2002, Myristoyl-CoA:protein N-myristoyltransferase: A novel molecular approach for cancer therapy (Review), Int J Mol Med, 10, 493 Shaham, 2003, The reinstatement model of drug relapse: History, methodology and major findings, Psychopharmacology (Berl), 168, 3, 10.1007/s00213-002-1224-x Sherwood, 2015, Deletion of Melanin Concentrating Hormone Receptor-1 disrupts overeating in the presence of food cues, Physiol Behav, 152, 402, 10.1016/j.physbeh.2015.05.037 Shimano, 1996, Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a, J Clin Invest, 98, 1575, 10.1172/JCI118951 Shinohara, 2004, Eating disorders with binge-eating behaviour are associated with the s allele of the 3′-UTR VNTR polymorphism of the dopamine transporter gene, J Psychiatry Neurosci, 29, 134 Shippenberg, 2002, Recent advances in animal models of drug addiction and alcoholism, 1381 Shram, 2011, Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users, Clin Pharmacol Ther, 89, 683, 10.1038/clpt.2011.20 Siebenhofer, 2009, Long-term effects of weight-reducing drugs in hypertensive patients, Cochrane Database Syst Rev, CD007654 Simmons, 2005, Pictures of appetizing foods activate gustatory cortices for taste and reward, Cereb Cortex, 15, 1602, 10.1093/cercor/bhi038 Simon, 1997, A possible role for tyrosine kinases in the regulation of the neuronal dopamine transporter in mouse striatum, Neurosci Lett, 224, 201, 10.1016/S0304-3940(97)13479-6 Sin, 1997, The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2, Proc Natl Acad Sci U S A, 94, 6099, 10.1073/pnas.94.12.6099 Sinal, 2000, Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis, Cell, 102, 731, 10.1016/S0092-8674(00)00062-3 Sinnayah, 2007, Bupropion and naltrexone interact synergistically to decrease food intake in mice Sjostrom, 1998, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group, Lancet, 352, 167, 10.1016/S0140-6736(97)11509-4 Skibicka, 2013, The central GLP-1: implications for food and drug reward, Front Neurosci, 7, 181, 10.3389/fnins.2013.00181 Skibicka, 2011, Ghrelin directly targets the ventral tegmental area to increase food motivation, Neuroscience, 180, 129, 10.1016/j.neuroscience.2011.02.016 Skibicka, 2012, Role of ghrelin in food reward: Impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression, Addict Biol, 17, 95, 10.1111/j.1369-1600.2010.00294.x Skibicka, 2012, Ghrelin interacts with neuropeptide Y Y1 and opioid receptors to increase food reward, Endocrinology, 153, 1194, 10.1210/en.2011-1606 Skibicka, 2013, Divergent circuitry underlying food reward and intake effects of ghrelin: dopaminergic VTA-accumbens projection mediates ghrelin's effect on food reward but not food intake, Neuropharmacology, 73, 274, 10.1016/j.neuropharm.2013.06.004 Small, 2003, Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers, Neuroimage, 19, 1709, 10.1016/S1053-8119(03)00253-2 Small, 2001, Changes in brain activity related to eating chocolate: From pleasure to aversion, Brain, 124, 1720, 10.1093/brain/124.9.1720 Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, Circulation, 124, 2458, 10.1161/CIR.0b013e318235eb4d Smith, 2010, Multicenter, placebo-controlled trial of lorcaserin for weight management, N Engl J Med, 363, 245, 10.1056/NEJMoa0909809 Sohn, 2013, Neuronal circuits that regulate feeding behavior and metabolism, Trends Neurosci, 36, 504, 10.1016/j.tins.2013.05.003 Sohn, 2015, Network of hypothalamic neurons that control appetite, BMB Rep, 48, 229, 10.5483/BMBRep.2015.48.4.272 Spiegelman, 2001, Obesity and the regulation of energy balance, Cell, 104, 531, 10.1016/S0092-8674(01)00240-9 Stanley, 1986, Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity, Peptides, 7, 1189, 10.1016/0196-9781(86)90149-X Stanley, 2005, Hormonal regulation of food intake, Physiol Rev, 85, 1131, 10.1152/physrev.00015.2004 Steinert, 2010, Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects, Am J Clin Nutr, 92, 810, 10.3945/ajcn.2010.29663 Sternbach, 1991, The serotonin syndrome, Am J Psychiatry, 148, 705, 10.1176/ajp.148.6.705 Stice, 2008, Relation of reward from food intake and anticipated food intake to obesity: A functional magnetic resonance imaging study, J Abnorm Psychol, 117, 924, 10.1037/a0013600 Sulzer, 2005, Mechanisms of neurotransmitter release by amphetamines: A review, Prog Neurobiol, 75, 406, 10.1016/j.pneurobio.2005.04.003 Sweeting, 2014, Management of obesity and cardiometabolic risk — Role of phentermine/extended release topiramate, Diabetes Metab Syndr Obes, 7, 35 Szabo, 2002, Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids, Eur J Neurosci, 15, 2057, 10.1046/j.1460-9568.2002.02041.x Tabarin, 2005, Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: Evidence for a “thrifty gene”, Diabetes, 54, 3510, 10.2337/diabetes.54.12.3510 Taha, 1999, The insulin signaling pathway, J Membr Biol, 169, 1, 10.1007/PL00005896 Tan, 2002, Melanin-concentrating hormone receptor subtypes 1 and 2: Species-specific gene expression, Genomics, 79, 785, 10.1006/geno.2002.6771 Tan, 2013, Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia, Diabetes, 62, 1131, 10.2337/db12-0797 Tartaglia, 1995, Identification and expression cloning of a leptin receptor, OB-R, Cell, 83, 1263, 10.1016/0092-8674(95)90151-5 Taylor, 2013, Lorcaserin for weight management, Diabetes Metab Syndr Obes, 6, 209, 10.2147/DMSO.S36276 Tedesco, 2008, Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes, Diabetes, 57, 2028, 10.2337/db07-1623 Ten Kulve, 2015, Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes, Diabetes Care, 10.2337/dc15-0772 Theander-Carrillo, 2006, Ghrelin action in the brain controls adipocyte metabolism, J Clin Invest, 116, 1983, 10.1172/JCI25811 Thomas, 2009, TGR5-mediated bile acid sensing controls glucose homeostasis, Cell Metab, 10, 167, 10.1016/j.cmet.2009.08.001 Thomsen, 1999, Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects, Am J Clin Nutr, 69, 1135, 10.1093/ajcn/69.6.1135 Torgerson, 2004, XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Torres, 2007, Relationship between stress, eating behavior, and obesity, Nutrition, 23, 887, 10.1016/j.nut.2007.08.008 Trivedi, 1998, Distribution of orexin receptor mRNA in the rat brain, FEBS Lett, 438, 71, 10.1016/S0014-5793(98)01266-6 Tsuchida, 2004, Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity, J Biol Chem, 279, 30817, 10.1074/jbc.M402367200 Veldhuis, 1991, Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man, J Clin Endocrinol Metab, 72, 51, 10.1210/jcem-72-1-51 Vergoni, 1999, Corticotropin-releasing factor (CRF) induced anorexia is not influenced by a melanocortin 4 receptor blockage, Peptides, 20, 509, 10.1016/S0196-9781(99)00022-4 Verty, 2013, Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice, Int J Obes (Lond), 37, 279, 10.1038/ijo.2012.35 Volkow, 2007, Issues for DSM-V: Should obesity be included as a brain disorder?, Am J Psychiatry, 164, 708, 10.1176/ajp.2007.164.5.708 Volkow, 2002, Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect, Synapse, 44, 175, 10.1002/syn.10075 Volkow, 2008, Overlapping neuronal circuits in addiction and obesity: Evidence of systems pathology, Philos Trans R Soc Lond B Biol Sci, 363, 3191, 10.1098/rstb.2008.0107 Volkow, 2012, Food and drug reward: Overlapping circuits in human obesity and addiction, Curr Top Behav Neurosci, 11, 1, 10.1007/7854_2011_169 Volkow, 2009, Inverse association between BMI and prefrontal metabolic activity in healthy adults, Obesity (Silver Spring), 17, 60, 10.1038/oby.2008.469 Volkow, 2005, How can drug addiction help us understand obesity?, Nat Neurosci, 8, 555, 10.1038/nn1452 von der Goltz, 2010, Orexin and leptin are associated with nicotine craving: A link between smoking, appetite and reward, Psychoneuroendocrinology, 35, 570, 10.1016/j.psyneuen.2009.09.005 Vrieze, 2012, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome, Gastroenterology, 143 Wang, 2007, Brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus reduces energy intake, Am J Physiol Regul Integr Comp Physiol, 293, R1003, 10.1152/ajpregu.00011.2007 Wang, 2014, Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues, Int J Obes (Lond), 38, 682, 10.1038/ijo.2013.145 Wang, 2002, The role of dopamine in motivation for food in humans: Implications for obesity, Expert Opin Ther Targets, 6, 601, 10.1517/14728222.6.5.601 Wang, 2001, Brain dopamine and obesity, Lancet, 357, 354, 10.1016/S0140-6736(00)03643-6 Ward, 2006, Mu-opioid receptor cellular function in the nucleus accumbens is essential for hedonically driven eating, Eur J Neurosci, 23, 1605, 10.1111/j.1460-9568.2006.04674.x Warwick, 1995, Determinants of high-fat diet hyperphagia: Experimental dissection of orosensory and postingestive effects, Am J Physiol, 269, R30 Weissman, 1998, An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group, N Engl J Med, 339, 725, 10.1056/NEJM199809103391103 Wellman, 2000, Norepinephrine and the control of food intake, Nutrition, 16, 837, 10.1016/S0899-9007(00)00415-9 Whitehouse, 2002, A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes, Diabetes Care, 25, 724, 10.2337/diacare.25.4.724 WHO Willesen, 1999, Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat, Neuroendocrinology, 70, 306, 10.1159/000054491 Williams, 2014, Neural integration of satiation and food reward: Role of GLP-1 and orexin pathways, Physiol Behav, 136, 194, 10.1016/j.physbeh.2014.03.013 Williams, 1984, Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction, N Engl J Med, 311, 1403, 10.1056/NEJM198411293112203 Williams, 2012, From neuroanatomy to behavior: Central integration of peripheral signals regulating feeding behavior, Nat Neurosci, 15, 1350, 10.1038/nn.3217 Williams, 1989, Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozocin-induced diabetic rats, Diabetes, 38, 321, 10.2337/diab.38.3.321 Willie, 2001, To eat or to sleep? Orexin in the regulation of feeding and wakefulness, Annu Rev Neurosci, 24, 429, 10.1146/annurev.neuro.24.1.429 Wittmann, 2007, Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus, J Comp Neurol, 503, 270, 10.1002/cne.21383 Woods, 1974, Metabolic hormones and regulation of body weight, Psychol Rev, 81, 26, 10.1037/h0035927 Woods, 2003, Insulin and the blood–brain barrier, Curr Pharm Des, 9, 795, 10.2174/1381612033455323 Wotherspoon, 2005, Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons, Neuroscience, 135, 235, 10.1016/j.neuroscience.2005.06.009 Wren, 2000, The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion, Endocrinology, 141, 4325, 10.1210/endo.141.11.7873 Wynne, 2005, Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: A double-blind, randomized, controlled trial, Diabetes, 54, 2390, 10.2337/diabetes.54.8.2390 Wynne, 2005, Appetite control, J Endocrinol, 184, 291, 10.1677/joe.1.05866 Xu, 2003, Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor, Nat Neurosci, 6, 736, 10.1038/nn1073 Yamauchi, 2003, Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, Nature, 423, 762, 10.1038/nature01705 Yang, 2001, Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin, J Clin Endocrinol Metab, 86, 3815, 10.1210/jcem.86.8.7741 Yanovski, 2014, Long-term drug treatment for obesity: A systematic and clinical review, JAMA, 311, 74, 10.1001/jama.2013.281361 Yeh, 2006, Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest, Proc Natl Acad Sci U S A, 103, 10379, 10.1073/pnas.0511313103 Yeo, 1998, A frameshift mutation in MC4R associated with dominantly inherited human obesity, Nat Genet, 20, 111, 10.1038/2404 Yin, 2004, Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning, Eur J Neurosci, 19, 181, 10.1111/j.1460-9568.2004.03095.x Zhang, 2006, The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist, Eur J Pharmacol, 545, 147, 10.1016/j.ejphar.2006.06.069 Zhang, 2003, Nucleus accumbens opioid, GABAergic, and dopaminergic modulation of palatable food motivation: contrasting effects revealed by a progressive ratio study in the rat, Behav Neurosci, 117, 202, 10.1037/0735-7044.117.2.202 Zhang, 1998, Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens, J Pharmacol Exp Ther, 285, 908 Zhang, 1994, Positional cloning of the mouse obese gene and its human homologue, Nature, 372, 425, 10.1038/372425a0 Zheng, 2005, Orexin-A projections to the caudal medulla and orexin-induced c-Fos expression, food intake, and autonomic function, J Comp Neurol, 485, 127, 10.1002/cne.20515 Zhi, 1996, Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers, J Clin Pharmacol, 36, 1006, 10.1177/009127009603601104 Zorrilla, 2006, Vaccination against weight gain, Proc Natl Acad Sci U S A, 103, 13226, 10.1073/pnas.0605376103